Related topics

Bellicum Pharmaceuticals: 2Q Earnings Snapshot

August 7, 2018

HOUSTON (AP) _ Bellicum Pharmacueticals Inc. (BLCM) on Tuesday reported a loss of $24.2 million in its second quarter.

On a per-share basis, the Houston-based company said it had a loss of 60 cents.

The results fell short of Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 57 cents per share.

The drug developer posted revenue of $362,000 in the period, exceeding Street forecasts. Three analysts surveyed by Zacks expected $76,000.

Bellicum Pharmaceuticals shares have declined 28 percent since the beginning of the year. In the final minutes of trading on Tuesday, shares hit $6.06, a decline of 44 percent in the last 12 months.


This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on BLCM at https://www.zacks.com/ap/BLCM

Update hourly